Abstract
Coronary drug-eluting stent development has included new metal alloys, changes in stent architecture and bioresorbable polymers. Whether these advancements improve clinical safety and efficacy has not been demonstrated in prior randomized trials. BIOFLOW V ([ClinicalTrials.gov][1] [NCT02389946][2
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
